As per our recommendations, if anybody in clinical practice encounters a patient with documented resistance to all these drugs or the majority of them, then a different regimen should be designed based on the few medications that are known to be active.
WSJ: The WHO Supports India's Fight Against MDR-TB �� Letters to the Editor